Duzon Bizon-Meditrix Collaborate on Digital Therapeutic Device Development

Duzon Bizon announced on the 15th that it has signed a memorandum of understanding (MOU) with Meditrix at Duzon Eulji Tower in Jung-gu, Seoul, to develop ‘digital therapeutic devices and wellness devices’ based on a cloud platform. Meditrix is a medical device and digital therapeutic device development company founded by Professor Jeon Hong-jin of the Department of Psychiatry at Samsung Seoul Hospital.

This agreement was established to build an organic cooperation system necessary for the two companies to promote two tasks: the development of digital therapeutic devices for depression cognitive behavioral therapy and wellness devices.

Digital therapeutic devices refer to software medical devices that allow therapeutic interventions such as doctor prescriptions for the purpose of preventing, managing, or treating patients’ medical disabilities or diseases. Compared to existing new drugs, they can be developed quickly and have the advantage of helping more patients. Due to the improvement of healthcare system efficiency and reduction of medical expenses, digital healthcare demand is increasing, and it has recently been recognized as a third-generation therapeutic agent.

The two companies will develop digital therapeutic devices that enable patients to recognize their own depressive disorder status and perform self-management and treatment by linking various wearable devices and mobile devices. They will provide not only cognitive behavioral therapy recommended in clinical treatment guidelines but also data reports analyzing daily life biometric signals using artificial intelligence technology. Accordingly, it is expected that patient status tracking and customized medical care by medical staff will become possible.

Subsequently, aiming for the commercialization of digital therapeutic devices, they will also pursue approval from the Ministry of Food and Drug Safety. To this end, the two companies plan to conduct clinical trials to secure safety and efficacy so that the digital therapeutic devices for depression can be effectively prescribed in actual hospital clinical settings.

They will also jointly start developing wellness devices, which are mental health management devices for the general public. Wellness devices are platforms that provide content such as cases, meditation, music, sounds, and lectures for mental health self-management. They measure biometric signals with various personal devices and provide analysis results, based on which they recommend video content for mental health management. In the future, business expansion for employee welfare, such as Employee Assistance Programs (EAP) based on Duzon Bizon’s corporate customers, is also expected.

Jeon Hong-jin, CEO of Meditrix, said, “With the increasing demand for digital healthcare, major countries are already creating clinical evidence through the development and market expansion of digital therapeutic devices,” adding, “We will take the lead in showcasing innovative medical devices by combining Meditrix’s expertise in mental health and Duzon Bizon, a leading domestic ICT company’s technological capabilities.”

Song Ho-chul, CEO of Duzon Bizon’s Platform Business Division, said, “Digital therapeutic devices are used in clinical fields such as therapeutic management of behavioral correction or chronic diseases where drug development is difficult, and patient data collection and analysis, which can improve healthcare system efficiency and reduce medical expenses, thereby enhancing social benefits at the national level,” adding, “We will mobilize accumulated ICT capabilities to contribute to enhancing the competitiveness of the medical industry.”

This content was produced with the assistance of AI translation services.